Concepedia

Neal E. Rothschild

NE

Statistics

Publications

3

Citations

179

H-Index

3

Active since

1989

Affiliations

Celldex Therapeutics (United States)(Current)

Florida Cancer Specialists & Research Institute

Tennessee Oncology

Vanderbilt University

Dana-Farber Cancer Institute

Neal E. Rothschild is an author at Celldex Therapeutics (United States) specializing in melanoma pharmacotherapy, immune checkpoint inhibitors, and mek inhibitors.

Publications per year

1989–2019

3

Publications

3

Fatal portuguese man-o'-war (Physalia physalis) envenomation

Mark R. Stein, John V. Marraccini, Neal E. Rothschild et al. · Annals of Emergency Medicine · 1989 · 93 citations

, , +4

A phase 2 study of glembatumumab vedotin, an antibody‐drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma

Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson et al. · Cancer · 2019 · 75 citations · Full text

, , +17

A phase II study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma.

Patrick A. Ott, Anna C. Pavlick, Douglas B. Johnson et al. · Journal of Clinical Oncology · 2017 · 11 citations

, , +17

1–3 of 3